- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04319276
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
November 2, 2023 updated by: Jennifer Connelly, MD, Medical College of Wisconsin
A Phase 1 Clinical Trial of Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).
Study Overview
Status
Recruiting
Conditions
Detailed Description
This is a prospective, single-center, single-arm, open-label phase 1 study to determine the antineoplastic activity, safety and tolerance of GaM in participants with relapsed, treatment-refractory GBM.
Although GaM has been studied in previous phase 1 clinical trials in normal individuals and in participants with a variety of different solid tumors, it has never been evaluated in this population of participants.
Dosages in this study have been defined to have limited side effects in other phase 1 trials.
The maximum number of participants to enroll in the dose escalation part will not exceed 36.
The trial will follow a 3 + 3 phase I dose escalation design.
Study Type
Interventional
Enrollment (Estimated)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Medical College of Wisconsin Cancer Center Clinical Trials Office
- Phone Number: 8900 866-680-0505
- Email: cccto@mcw.edu
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Froedtert Hospital & the Medical College of Wisconsin
-
Contact:
- Cancer Center Clinical Trials Office
- Phone Number: 8900 866-680-0505
- Email: cccto@mcw.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
- Voluntary written consent must be obtained before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.
- All patients must have a prior histological diagnosis of GBM (WHO grade IV) or molecular features of GBM (per the 6th volume of Central Nervous System Tumors in the 5th edition of the WHO Classification of Tumors).
- Patients are required to have received standard treatment which consists of radiotherapy and temozolomide [i.e., the Stupp Protocol (3)] Treatment with adjuvant temozolimide must be completed at least four weeks prior to GaM administration to avoid potential for overlapping toxicity with GaM. Although the half-life (T½) of temozolomide is 1.8 hours and it would be expected to be cleared by five half-lives, some patients receiving temozolomide may experience a delayed suppression of their ANC. Hence, a four-week interval between completion of temozolomide and GaM will be required. There is no maximum limit to the amount of chemotherapy or radiation patients have received prior to enrollment.
- Patients must have measurable disease that can be assessed for response to treatment as defined by the Response Assessment in Neuro-Oncology (RANO) criteria which incorporates MRI assessment and clinical factors. In the absence of measurable disease, pathologic confirmation of recurrent disease is required.
- Male or female subjects must be ≥18 years of age.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
Patients must have adequate bone marrow function as evidenced by:
- an absolute neutrophil count (ANC) of >1500/μL (stable off any growth factor within one week of study drug administration
- Hemoglobin > 9 g/dL
- Platelet count > 100.000/μL without transfusion within one week
- Patients must have adequate hepatic and renal function based on the following laboratory tests: a. alanine transaminase (ALT) ≤ 2 x upper limits of normal (ULN) b. aspartate aminotransferase (AST) ≤ 2 x ULN c. Alkaline phosphatase ≤ 2 x ULN d. Total bilirubin ≤ 2 x ULN e. Creatinine < 1.5 mg/dL or glomerular filtration rate (GFR) by Modification of Diet in Renal Disease (MDRD) > 45
Female subjects must meet one of the following:
- Postmenopausal for at least one year before enrollment, OR
- Surgically sterile (i.e., undergone a hysterectomy or bilateral oophorectomy), OR
- If subject is of childbearing potential (defined as not satisfying either of the above two criteria), agree to practice two acceptable methods of contraception (combination methods require use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 21days after the last dose of study agent, OR
- Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)
Male subjects, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:
- Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR
- Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
- Patients taking oral iron supplements or iron chelators must discontinue these medications at least one week prior to starting GaM since these agents may impact on the efficacy of GaM. Drug-drug interactions between GaM and other concomitant medications have not been reported.
Exclusion Criteria
- Presence of other active malignant disease diagnosed within 12 months, with the exception of adequately treated non-melanoma skin cancer, adequately treated melanoma grade 2 or less, or cervical intraepithelial neoplasia. Active malignancy is malignancy receiving treatment.
- Prior chemotherapy or radiotherapy within 14 days of study entry.
- Known hypersensitivity to or intolerance to gallium-based medications.
- Concurrent use of cytotoxic chemotherapy is not permitted.
- Unstable or severe concurrent medical conditions such as severe heart (New York Heart Association Class 3 or 4) or known lung (FEV <50%) disease, uncontrolled diabetes mellitus.
- History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or symptomatic pleural effusion.
- Patients who have not completed all standard-of-care treatments including surgical procedures and radiation therapy.
- Inability to tolerate an oral medication or keep pills down.
- Patients who are pregnant or nursing.
- Patients with any condition which, in the investigator's opinion, makes the patient unsuitable for study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose-escalation Phase (500 mg)
This is a 3 + 3 design.
Participants will be entered sequentially.
If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level.
If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level.
If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level.
If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD).
If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose.
If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD.
The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
|
This is a 3+3 design.
The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Other Names:
|
Experimental: Dose-escalation Phase (1,000 mg)
This is a 3 + 3 design.
Participants will be entered sequentially.
If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level.
If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level.
If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level.
If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD).
If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose.
If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD.
The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
|
This is a 3+3 design.
The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Other Names:
|
Experimental: Dose-escalation Phase (1,500 mg)
This is a 3 + 3 design.
Participants will be entered sequentially.
If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level.
If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level.
If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level.
If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD).
If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose.
If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD.
The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
|
This is a 3+3 design.
The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Other Names:
|
Experimental: Dose-expansion Phase
A minimum of six participants will be enrolled in the dose expansion phase for a total of 12 subjects at the recommended phase 2 dose.
|
The maximum-tolerated dose (recommended phase 2 dose).
Other Names:
|
Experimental: Dose-escalation Phase (2,000 mg)
This is a 3 + 3 design.
Participants will be entered sequentially.
If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level.
If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level.
If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level.
If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD).
If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose.
If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD.
The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
|
This is a 3+3 design.
The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Other Names:
|
Experimental: Dose-escalation Phase (2,500 mg)
This is a 3 + 3 design.
Participants will be entered sequentially.
If 0 of 3 participants has a dose-limiting toxicity (DLT), new participants may be entered at the next higher dose level.
If 1 of 3 participants has a DLT, up to 3 more participants are to be treated at that same dose level.
If 0 of the additional 3 participants at that dose level has a DLT, new participants may be entered at the next higher dose level.
If 1 or more of the additional 3 participants experience a DLT, 0 participants are to be started at that dose level and the preceding dose is the maximum-tolerated dose (MTD).
If 2 of 3 of the dosed participants has a DLT on the first dose level, the drug will be administered at a lower dose.
If 0 of 3 participants has a DLT at the highest dose level, an additional 3 participants will be enrolled to ensure that 6 participants are treated at the MTD.
The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a DLT.
|
This is a 3+3 design.
The doses are as follows: level -1: 500 mg every other day; level 0: (starting dose) 500 mg daily; level 1: 1,000 mg daily; level 2: 1,500 mg daily; level 3: 2,000 mg daily; level 4: 2,500 mg daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum-tolerated dose.
Time Frame: Each 28-day cohort
|
This will be determined from the incidence of dose limiting toxicities at each dosage.
|
Each 28-day cohort
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: 6 months
|
This measure is the number of months participants remain free from evidence of disease.
Imaging will be done every eight weeks and reported at six months.
|
6 months
|
Overall survival
Time Frame: 6 months
|
Overall survival is determined as the average number of months subjects survived following enrollment.
|
6 months
|
Dose-limiting toxicity
Time Frame: 28 days for each cohort
|
Number of participants experiencing a dose limiting toxicity.
|
28 days for each cohort
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jennifer Connelly, MD, Medical College of Wisconsin
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 11, 2022
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2026
Study Registration Dates
First Submitted
March 20, 2020
First Submitted That Met QC Criteria
March 20, 2020
First Posted (Actual)
March 24, 2020
Study Record Updates
Last Update Posted (Actual)
November 7, 2023
Last Update Submitted That Met QC Criteria
November 2, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO00041263
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Gallium maltolate (recommended phase 2 dose)
-
Millennium Pharmaceuticals, Inc.Completed
-
Basilea PharmaceuticaArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...CompletedSolid TumorUnited States, Italy
-
CHU de Quebec-Universite LavalCanadian Institutes of Health Research (CIHR)Not yet recruitingCancer | Prostate Cancer | Metastatic Cancer | Metastatic Prostate Cancer
-
Scripps Clinic Cancer CenterThreshold PharmaceuticalsUnknownHepatocellular CarcinomaUnited States
-
Benitec Biopharma, Inc.RecruitingOculopharyngeal Muscular DystrophyUnited States
-
Institut BergoniéBayer; Merck KGaA, Darmstadt, GermanyRecruitingHepatocellular Carcinoma | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Soft-tissue Sarcoma | Urothelial Carcinoma | Thyroid Cancer | Gastro-enteropancreatic Neuroendocrine Tumor | Biliary Tract Cancer | HPV-Related Carcinoma | Solid Tumor, Adult | Mesotheliomas Pleural | GIST | Renal Carcinoma | Colorectal... and other conditionsFrance
-
Jill M KolesarArtemiLifeRecruiting
-
Supernus Pharmaceuticals, Inc.Solstice NeurosciencesActive, not recruitingSpasticityUnited States, Czechia
-
Supernus Pharmaceuticals, Inc.Solstice NeurosciencesActive, not recruitingMultiple Sclerosis | Cerebral Palsy | Traumatic Brain Injury | Cerebrovascular Accident | Cervical Spinal Cord Injury | SpasticityUnited States, Czechia
-
Mirati Therapeutics Inc.TerminatedAdvanced CancerUnited States